Company intelligence / Profile preview
Jiangsu Nhwa Pharmaceutical
Xuzhou, Jiangsu, Chinaen.nhwa-group.com ↗
- Ownership
- Public · 002262
- Employees
- ~5923
- Development stage
- Commercial
01
Overview
Market leader in CNS drugs with commercial products and late-stage partnerships including FDA-approved AUSTEDO® commercialization in China[4][7]. Maintains three GMP production bases producing APIs and formulations[2].
- Therapeutic areas
- OtherPsychiatryCardiovascularNeurology
- Modalities
- Small moleculesBiologics (via Teva partnership)
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
03
Partnerships
Teva Pharmaceutical Industries Ltd.:Commercialization of AUSTEDO® in China(2024)Trevena Inc.:Development/commercialization of OLINVYK® in China(2018-)National Academy of Military Medical SciencesIptakalim development
04
Financials
- Market cap
- $3.5B
- Total revenue
- $877M
- Enterprise value
- $2.9B
Beyond the preview
Go deeper on Jiangsu Nhwa Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jiangsu Nhwa Pharmaceutical.